TrialAntimicrobial agents and chemotherapy2026

First-in-human safety and pharmacokinetics of MK-7602, the antimalarial inhibitor of plasmepsins IX/X, in single- and multiple-ascending-dose studies.

Susan E Stanley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.